Fundamental Data for POZN

Pozen Inc. is pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. Its initial area of focus is migraine, where the company have built a portfolio of four product candidates through a combination of innovation and in-licensing. Its lead product candidate is MT 100, which the company is developing as an oral first-line therapy for the treatment of migraine.

# Employees: 35

Address: 1414 Raleigh Road Suite 400,Chapel Hill,NC,USA

Phone: 919 913-1030

Fax: 919 913-1039

Website: www.pozen.com

Email: investor@pozen.com

Sector: Medical

Industry: MED-DRUGS

Executive Officers

John R. Plachetka (Chmn.; Presi.; C.E.O.)

William L. Hodges (Sr. V.P.; Fin. & Admn.; C.F.O.)

John E. Barnhardt (V.P.;Fin. & Admn.)

Arthur S. Kirsch (Dir.)

Kenneth B. Lee Jr. (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/24/2010

Mean EPS (Next Qtr): ($0.19)

Mean EPS (Year): ($0.23)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 7

Shares Performance

Period	POZN	Compare to S&P
YTD	37.90 %	14.13 %
4 Weeks	7.25 %	6.10 %
12 Weeks	7.42 %	1.27 %

Shares Information

Analyst Coverage: Y

Avg Volume: 105073

Shares Outstanding: 29M

Market Cap: $0.21B

52 Week High: $8.22

52 Week Low: $4.75

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 POZN split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 257.14 %

EPS Growth in Last Year: 184.62 %

Sales Growth in Last Quarter: 190.68 %

Sales Growth in Last Quarter: 28.22 %

Financials

Qtr Book Value: $5.41

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 4.940